Pioglitazone

Thiazolidinedione (PPAR-γ agonist), oral antidiabetic

ATC code: A10BG03

Brand names: Actoplus Met, Actos, Duetact

Updated 24 Sep 2026 · Methodology

Indications

Type 2 diabetes mellitus

Third line

Oral antidiabetic for type 2 diabetes. The redGDPS 2024 algorithm positions pioglitazone as a third-line option after metformin and GLP-1 RA / SGLT-2i in insulin-resistant patients, particularly with concomitant non-alcoholic fatty liver disease. In Spanish practice it is used less than GLP-1 agonists because of weight gain, oedema, heart failure and fracture risk. PROactive 2005 showed a 16% reduction in a composite cardiovascular endpoint but no significant effect on the primary endpoint.

Sources

ICD-10: E11 · ICD-11: 5A11

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Anti-aging and longevity

Not recommended

Pioglitazone is a thiazolidinedione antidiabetic. AEMPS authorises it only for type 2 diabetes. Biohacking and longevity-stack communities promote pioglitazone as an «anti-aging drug» on the basis of improved insulin sensitivity and reduced systemic inflammation. The link is not confirmed: pioglitazone is not in the TAME protocol (which tests metformin) and there are no completed lifespan RCTs in non-diabetic adults. Use without a diagnosis carries real risks: 3–4 kg weight gain, oedema, heart failure, bladder cancer (cumulative risk with long use), distal-bone fractures in postmenopausal women (twofold vs metformin), macular oedema. If pioglitazone was prescribed for «longevity» – consider seeking a second opinion.

Sources

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Selective agonist of nuclear PPAR-γ receptor. Activates transcription of insulin-sensitivity genes in adipocytes, skeletal muscle and liver: upregulates GLUT-4 expression, increases peripheral glucose uptake and suppresses gluconeogenesis. Reduces circulating free fatty acids and redistributes fat from visceral to subcutaneous depots. Effect develops over 6–8 weeks. Does not stimulate insulin secretion and does not cause hypoglycaemia as monotherapy.

Safety

Contraindications

Hypersensitivity to pioglitazone
Heart failure (any NYHA class)
Active or prior bladder cancer
Uninvestigated macrohaematuria
Hepatic impairment with ALT >2.5× ULN
Type 1 diabetes and diabetic ketoacidosis
Pregnancy and lactation

Serious adverse effects

Heart failure decompensation and pulmonary oedema
Bladder cancer (cumulative risk with use beyond 2 years)
Distal-bone fractures (especially in postmenopausal women)
Macular oedema with visual acuity reduction
Hepatotoxicity (rare)

Common adverse effects

Weight gain (3–4 kg in the first year)
Peripheral oedema
Upper respiratory tract infections
Headache
Hypoaesthesia
Reduced haematocrit (haemodilution)

Pregnancy: can you take Pioglitazone?

AEMPS summary of product characteristics (section 4.6): there are not enough human data to determine the safety of pioglitazone in pregnancy. Animal studies showed fetal growth restriction, attributed to pioglitazone reducing maternal hyperinsulinaemia and the increased insulin resistance of pregnancy, which leaves fewer metabolic substrates for fetal growth. The relevance of this mechanism in humans is unclear, so pioglitazone is not used during pregnancy.

Breastfeeding: can you take Pioglitazone?

Not preferred. Hale L4. Excreted in animal milk; human data are scarce. AEMPS contraindicates use during lactation. When antidiabetic therapy is needed in a breastfeeding mother, metformin (L1) and insulin (L1) are preferred.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Drug–drug interactions

1 pair found. Sorted from critical to minor.

MajorGemfibrozilLipid-lowering agent of the fibrate class

Mechanism

Pioglitazone is metabolised mainly by CYP2C8, and gemfibrozil is a strong inhibitor of that enzyme. Pioglitazone exposure rises, and its dose-dependent effects intensify with it: fluid retention and weight gain.

Symptoms

Ankle oedema, rapid weight gain, breathlessness on exertion and when lying down as a sign of decompensating heart failure. Hypoglycemia is possible when pioglitazone is taken with insulin or a sulfonylurea.

Management

The pioglitazone dose is reduced, as the label's general rule for CYP2C8 substrates requires. Weight and oedema are monitored from the first weeks of joint use. The combination is not used in heart failure.

Sources

Pair details →Gemfibrozil →

Label mentions30 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

MajorGemfibrozil
«Strong CYP2C8 Inhibitors: An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t 1/2 ) of…»
FDA, section 7 · Open on DailyMed
ModerateGemfibrozil
«La administración conjunta de pioglitazona y gemfibrozilo (un inhibidor del citocromo P450 2C8) produjo un incremento de tres veces el área bajo la curva de pioglitazona. Debido a que existe la…»
AEMPS, section 4.5 · Open on CIMA
ModerateInsulin
«Retención hídrica e insuficiencia cardiaca: La pioglitazona puede producir retención hídrica de fluidos; esto puede exacerbar o precipitar la insuficiencia cardiaca. Cuando se traten pacientes que…»
AEMPS, section 4.4 · Open on CIMA
Moderateinsulinaclass named in the label
«Retención hídrica e insuficiencia cardiaca: La pioglitazona puede producir retención hídrica de fluidos; esto puede exacerbar o precipitar la insuficiencia cardiaca. Cuando se traten pacientes que…»
AEMPS, section 4.4 · Open on CIMA
ModerateRifampicin
«La administración conjunta de pioglitazona y gemfibrozilo (un inhibidor del citocromo P450 2C8) produjo un incremento de tres veces el área bajo la curva de pioglitazona. Debido a que existe la…»
AEMPS, section 4.5 · Open on CIMA
Moderatesulfonilureasclass named in the label
«Hipoglucemia: Como consecuencia de un aumento de la sensibilidad a la insulina, los pacientes que reciban pioglitazona en doble o triple terapia oral con una sulfonilurea o terapia combinada con…»
AEMPS, section 4.4 · Open on CIMA
ModerateTopiramate
«Topiramate: A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate [see ] . The clinical relevance of this…»
FDA, section 7 · Open on DailyMed
anticonceptivos hormonalesclass named in the label
«Los estudios sobre interacciones han demostrado que la pioglitazona no afecta de forma relevante ni a la farmacocinética ni a la farmacodinamia de la digoxina, warfarina, fenprocumón ni metformina…»
AEMPS, section 4.5 · Open on CIMA
Ciclosporin
«Los estudios sobre interacciones han demostrado que la pioglitazona no afecta de forma relevante ni a la farmacocinética ni a la farmacodinamia de la digoxina, warfarina, fenprocumón ni metformina…»
AEMPS, section 4.5 · Open on CIMA
Digoxin
«Los estudios sobre interacciones han demostrado que la pioglitazona no afecta de forma relevante ni a la farmacocinética ni a la farmacodinamia de la digoxina, warfarina, fenprocumón ni metformina…»
AEMPS, section 4.5 · Open on CIMA
estatinasclass named in the label
«Los estudios sobre interacciones han demostrado que la pioglitazona no afecta de forma relevante ni a la farmacocinética ni a la farmacodinamia de la digoxina, warfarina, fenprocumón ni metformina…»
AEMPS, section 4.5 · Open on CIMA
Metformin
«Los estudios sobre interacciones han demostrado que la pioglitazona no afecta de forma relevante ni a la farmacocinética ni a la farmacodinamia de la digoxina, warfarina, fenprocumón ni metformina…»
AEMPS, section 4.5 · Open on CIMA
Warfarin
«Los estudios sobre interacciones han demostrado que la pioglitazona no afecta de forma relevante ni a la farmacocinética ni a la farmacodinamia de la digoxina, warfarina, fenprocumón ni metformina…»
AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

MajorGemfibrozil
«El perfil de interacciones de gemfibrozilo es complejo. Los estudios in vivo indican que gemfibrozilo y su metabolito gemfibrozilo 1-O-β-glucurónido son potentes inhibidores de CYP2C8 (un enzima…»
AEMPS, section 4.5 · Open on CIMA
ModerateAbiraterone
«Posibilidad de que afecte a la exposición de otros medicamentos: En un estudio de interacción CYP2C8 fármaco-fármaco en sujetos sanos, el AUC de pioglitazona aumentó un 46% y los AUCs de M-III y…»
AEMPS, section 4.5 · Open on CIMA
ModerateAbiraterone
«Effects of Abiraterone on Drug Metabolizing Enzymes: In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was…»
FDA, section 7 · Open on DailyMed
ModerateClarithromycin
«DRUG INTERACTIONS: Nateglinide Pioglitazone Repaglinide Rosiglitazone Use With Caution Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone: [See Warnings and Precautions (5.4) and Adverse Reactions…»
FDA, section 7 · Open on DailyMed
ModerateInsulin
«Combinación de Actrapid y pioglitazona: Cuando se utilizó pioglitazona en combinación con insulina, se notificaron casos de insuficiencia cardiaca, especialmente en pacientes con factores de riesgo…»
AEMPS, section 4.4 · Open on CIMA
ModerateInsulin aspart
«Combinación de pioglitazona e insulinas: Se han notificado casos de insuficiencia cardiaca congestiva al usar pioglitazona en combinación con insulina, especialmente en pacientes con factores de…»
AEMPS, section 4.4 · Open on CIMA
ModerateInsulin degludec
«Combinación de pioglitazona e insulinas: Cuando la pioglitazona fue utilizada en combinación con insulina, se notificaron casos de insuficiencia cardiaca, especialmente en pacientes con factores de…»
AEMPS, section 4.4 · Open on CIMA
ModerateInsulin detemir
«Combinación de Levemir y pioglitazona: Cuando pioglitazona fue utilizada en combinación con insulina, se notificaron casos de insuficiencia cardiaca, especialmente en pacientes con factores de riesgo…»
AEMPS, section 4.4 · Open on CIMA
ModerateInsulin lispro
«Combinación de Humalog con pioglitazona: Cuando pioglitazona fue utilizada en combinación con insulina se notificaron casos de insuficiencia cardiaca, especialmente en pacientes con factores de…»
AEMPS, section 4.4 · Open on CIMA
ModerateLeflunomide
«Dosis repetidas de A771726 aumentaron la C max media y la AUC (1,7- y 2,4-veces, respectivamente) de la repaglinida, sugiriendo que el A771726 es un inhibidor de CYP2C8 in vivo. Por tanto, se…»
AEMPS, section 4.5 · Open on CIMA
ModerateLeflunomide
«DRUG INTERACTIONS: Teriflunomide is an inhibitor of CYP2C8 in vivo . In patients taking leflunomide, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide…»
FDA, section 7 · Open on DailyMed
ModerateTopiramate
«Pioglitazona: En un estudio sobre interacciones farmacológicas realizado en voluntarios sanos se evaluaron las farmacocinéticas en estado estacionario de topiramato y pioglitazona administrados solos…»
AEMPS, section 4.5 · Open on CIMA
ModerateTopiramate
«Pioglitazone: A decrease in the exposure of pioglitazone and its active metabolites were noted with the concurrent use of pioglitazone and topiramate in a clinical trial. The clinical relevance of…»
FDA, section 7 · Open on DailyMed
Dapagliflozin
«En los estudios de interacción realizados en sujetos sanos, usando principalmente un diseño de dosis única, sugieren que la farmacocinética de dapagliflozina no se ve alterada por la metformina…»
AEMPS, section 4.5 · Open on CIMA
Empagliflozin
«Los estudios de interacciones sugieren que la farmacocinética de empagliflozina no se vio influida por la administración conjunta de metformina, glimepirida, pioglitazona, sitagliptina, linagliptina…»
AEMPS, section 4.5 · Open on CIMA
Vildagliptin
«Combinación con pioglitazona, metformina y gliburida: Los resultados de ensayos clínicos realizados con estos antidiabéticos orales no han mostrado interacciones farmacocinéticas relevantes.»
AEMPS, section 4.5 · Open on CIMA
Warfarin
«CYP450 Interactions: CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan…»
FDA, section 7 · Open on DailyMed

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Pioglitazone used for?

Pioglitazone is evaluated for the following indications with varying evidence strength: Type 2 diabetes mellitus (evidence tier B), Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Pioglitazone?

Common side effects of Pioglitazone (≥ 1 in 100): Weight gain (3–4 kg in the first year), Peripheral oedema, Upper respiratory tract infections, Headache, Hypoaesthesia, Reduced haematocrit (haemodilution). See the Safety section for uncommon and serious reactions.

Is Pioglitazone safe during pregnancy?

Is Pioglitazone compatible with breastfeeding?

Who should not take Pioglitazone?

Pioglitazone is contraindicated in: Hypersensitivity to pioglitazone; Heart failure (any NYHA class); Active or prior bladder cancer; Uninvestigated macrohaematuria; Hepatic impairment with ALT >2.5× ULN. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMALabel dated 10/20/2021
FDA / DailyMedLabel dated 08/17/2026

Other drugs in this group

Repaglinide, Semaglutide, Sitagliptin, Sitagliptin + Metformin, Empagliflozin, Insulin aspart, Insulin human isophane (NPH), Tirzepatide